Fate Therapeutics (FATE) Operating Expenses (2012 - 2026)

Fate Therapeutics' Operating Expenses history runs 15 years deep, the most recent figure standing at $34.3 million for Q1 2026.

• Quarterly Operating Expenses fell 20.07% year-over-year to $34.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $145.7 million (down 31.84% YoY) and the FY2025 annual result came in at $154.4 million, down 31.07% from the prior year.
• Operating Expenses was $34.3 million for Q1 2026 at Fate Therapeutics, down from $36.1 million in the prior quarter.
• Across five years, Operating Expenses topped out at $108.8 million in Q4 2022 and bottomed at $34.3 million in Q1 2026.
• A 5-year average of $63.0 million and a median of $53.2 million in 2023 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2022 — Operating Expenses soared 68.89% — and 2023, when it plunged 54.26%.
• Fate Therapeutics' Operating Expenses stood at $108.8 million in 2022, then plunged by 54.26% to $49.8 million in 2023, then rose by 27.85% to $63.6 million in 2024, then plunged by 43.26% to $36.1 million in 2025, then fell by 4.96% to $34.3 million in 2026.
• Business Quant data shows FATE's Operating Expenses at $34.3 million in Q1 2026, $36.1 million in Q4 2025, and $36.5 million in Q3 2025.